Seeking Alpha

Amarin jumps as CEO buys shares

  • Beleaguered Amarin (AMRN) gets a 7.8% bump AH on news CEO Joseph Zakrzewski bought 50,777 shares at $1.84 each.
Comments (16)
  • That is what I like to see from the CEO. We needed some insider buying and I hope to see more.
    18 Nov 2013, 04:43 PM Reply Like
  • $80,000. He's trying to get a little bit of the egg off his face with this PR stunt. He has made millions selling the stock and gets paid some half a million a year. Chump change for him and meaningless for AMRN. Just another good pop to sell into.
    18 Nov 2013, 04:45 PM Reply Like
  • OMG 80k!!!! what a guy.
    18 Nov 2013, 04:52 PM Reply Like
  • why buy stock when he can just award himself options for the fine work he has done.
    18 Nov 2013, 04:53 PM Reply Like
  • Corrupt FDA, this is the story, shame on FDA and USA:

     

    http://bit.ly/17GJ1ts
    18 Nov 2013, 05:22 PM Reply Like
  • His buy price for the 50k on 11-18-13 was 1.54, not 1.84 - check the PR.
    18 Nov 2013, 05:23 PM Reply Like
  • Wow, people even complain when he does something that is pretty much universally seen as a positive. It's amazing how rich everyone on this website is, that 80k is chump change.
    18 Nov 2013, 05:29 PM Reply Like
  • It's all relative. It's chump change to JoeZ. Heck, some of the investors on here had that much in AMRN stock themselves! The dude made millions selling the stock after approval and makes half a mil in salary and more in bonuses.

     

    Take the blinders off. It's a PR move. If he plowed the millions in cash that originally made from selling AMRN stock, then we are talking. $80k? No.
    18 Nov 2013, 05:50 PM Reply Like
  • I applaud Joe Z's small yet meaningful gesture. Investors were desperate for any sign of life from him and anything will do at this point.
    18 Nov 2013, 05:46 PM Reply Like
  • The man can't do anything right according to some of you ... you wanted an inside purchase, correct? he just might be telling you through this 'gesture' he appreciates all the efforts from the shareholder's visa vi the petitions, letters, news wires, etc .... use your imagination :).
    18 Nov 2013, 06:50 PM Reply Like
  • I admit that I would rather hear about a partnership to maximize sales of Vascepa for the Marine indication.140 sales reps cannot be expected to grow sales to the extent needed to complete the Reduce It study.
    18 Nov 2013, 07:04 PM Reply Like
  • not impress........ (((((
    18 Nov 2013, 07:26 PM Reply Like
  • it is better than the nothing he has accustomed us to throughout the fall since mid-2012, but i must say i find it rather pathetic.... First of all we should have seen inside buys at the latest around the 5-7 range which still made some sense given amrn's existing drug on the market for the >500, but to buy 50k at below 2 for a total of not even 100k$, come on....!
    At least when Berger from ariad bought additional shares last year (mind u, he had not sold a single share at that time, unlike amrn ceo) he bought if my memory is correct something like 2m$ worth....
    Now that's a man....
    Best, AC
    18 Nov 2013, 08:04 PM Reply Like
  • dont care.. sell the company for 15 to 20 bucks and get the investors their money back
    18 Nov 2013, 09:03 PM Reply Like
  • Did he buy to cover?
    18 Nov 2013, 09:33 PM Reply Like
  • The problem with $AMRN is that they're trying to sell a cure... and Big Pharma is not done selling the treatment for the symptoms.

     

    Yes, that's right: Big Pharma hasn't bought $AMRN because none of those companies want to sell cures. All of them want to sell ever-lasting treatments that never really cure anything.

     

    I should have never invested in a company trying to sell a cure for anything. Money in Healthcare is not done by curing people but by ensuring patients are somewhat relieved from the symptoms while they remain forever ill.
    19 Nov 2013, 04:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)